The canonical profile remains the primary reading view. Read the canonical profile.
We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027. 675
What this version reported
Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Reader guide in this version
Key takeaway
Melanotan II is a synthetic ring-shaped peptide of seven amino acids, recorded in FDA’s substance registry under the names Melanotan II and MT-II.1 Its human research is small and early: a 1996 pilot study in three men reported skin darkening and spontaneous erections, and a 2000 placebo-controlled study in 10 men with erectile dysfunction reported erections and nausea.6,7 FDA lists Melanotan II among compounding substances that may present significant safety risks, citing published case reports of serious adverse events including melanoma, a brain-swelling syndrome (PRES), a stimulant-like toxic reaction and priapism.2 No FDA approval is reported in the sources reviewed here, and Melanotan II is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4
At a glance
- What it is
- A synthetic cyclic peptide, N-acetyl-norleucyl-aspartyl-histidyl-D-phenylalanyl-arginyl-tryptophyl-lysinamide closed into a ring between its second and seventh units, according to FDA’s substance registry.1
- FDA status
- No FDA approval is reported in the sources reviewed here. FDA lists Melanotan II among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
- Human evidence
- Two very small early studies, published in 1996 and 2000, one of them placebo-controlled, plus published case reports of serious adverse events cited by FDA.2,6,7
- Evidence strength
- Smaller controlled human trials
What is Melanotan II?
Melanotan II is a synthetic peptide of seven units, N-acetyl-norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan and lysinamide, with a bond closing the chain into a ring, according to FDA’s substance registry.1
The researchers who first tested it in people describe it as a ring-shaped analogue of alpha-melanocyte stimulating hormone (alpha-MSH) with very potent pigment-stimulating (melanotropic) activity in laboratory tests.6
How is Melanotan II thought to work?
As an analogue of alpha-MSH, it was studied for its effect on skin pigmentation, according to the 1996 pilot study.6
The authors of the 2000 study describe it as a synthetic melanotropic peptide that initiates erections. The FDA sources reviewed here do not describe its mechanism.2,7
What do human studies show?
In a 1996 pilot study, three healthy men received Melanotan II or saline on alternating days for two weeks. Two had increased pigmentation of the face, upper body and buttocks; mild nausea was common, one had marked sleepiness and fatigue, and spontaneous erections followed stretching and yawning.6
In a 2000 double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, erections were reported after 12 of 19 Melanotan II treatments and 1 of 21 placebo treatments. Nausea and stretching or yawning were more common with Melanotan II, and 4 of 19 treatments caused severe nausea.7
FDA cites published case reports that discuss serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome (a form of brain swelling), sympathomimetic toxidrome (a stimulant-like poisoning) and priapism (a prolonged, painful erection).2
These studies were very small and short, and the FDA sources reviewed here do not evaluate whether Melanotan II is effective for any use.2,6,7
What the evidence base contains
- Controlled human trial A double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, published in 2000.7
- Small, short, or incompletely reported human study A 1996 single-blind, placebo-controlled pilot study in three healthy men over two weeks.6
- Small, short, or incompletely reported human study Published case reports, cited by FDA, of serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is Melanotan II FDA-approved?
None of the sources reviewed here reports an approval of Melanotan II by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists Melanotan II among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions from aggregation or impurities and the case reports above.2
FDA’s page for the next meeting of its Pharmacy Compounding Advisory Committee, current as of April 15, 2026, lists Melanotan II among substances the committee will discuss for the 503A bulks list at a meeting before the end of February 2027, with the date not yet set.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Melanotan II is not among them.3,4
Timeline
- Results of a pilot study of Melanotan II in three men are published.6
- Results of a placebo-controlled crossover study of Melanotan II in 10 men with erectile dysfunction are published.7
- FDA’s advisory committee page lists Melanotan II for discussion at a meeting before the end of February 2027.5
- FDA’s compounding safety-risk page, as last updated, lists Melanotan II among withdrawn nominations with safety concerns.2
What is still unknown?
How often the serious adverse events in the case reports occur, since case reports cannot measure frequency or prove cause.2
Whether it is effective or safe for any condition: the two human studies reviewed here enrolled 13 men in total.6,7
What FDA’s advisory committee will conclude; its page did not give a meeting date.5
Sources for this version
- 1Melanotan II substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 5Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 6Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (1996) · PMID 8637402 ↗
Life Sciences · Official source · Source checked November 16, 2026
- 7Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (2000) · PMID 11018622 ↗
Urology · Official source · Source checked November 16, 2026